These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30342319)

  • 1. Sequence-based analysis and prediction of lantibiotics: A machine learning approach.
    Poorinmohammad N; Hamedi J; Moghaddam MHAM
    Comput Biol Chem; 2018 Dec; 77():199-206. PubMed ID: 30342319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of lantibiotic biosynthetic machinery promiscuity and its impact on antimicrobial discovery.
    Sandiford SK
    Expert Opin Drug Discov; 2020 Mar; 15(3):373-382. PubMed ID: 31941374
    [No Abstract]   [Full Text] [Related]  

  • 4. Lantibiotics: promising candidates for future applications in health care.
    Dischinger J; Basi Chipalu S; Bierbaum G
    Int J Med Microbiol; 2014 Jan; 304(1):51-62. PubMed ID: 24210177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the importance of charged residues in lantibiotics.
    Suda S; Hill C; Cotter PD; Ross RP
    Bioeng Bugs; 2010; 1(5):345-51. PubMed ID: 21326835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction and characterisation of lantibiotic structures with molecular modelling and molecular dynamics simulations.
    Chakraborty HJ; Gangopadhyay A; Datta A
    Sci Rep; 2019 May; 9(1):7169. PubMed ID: 31073133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognizing and Predicting Thioether Bridges Formed by Lanthionine and β-Methyllanthionine in Lantibiotics Using a Random Forest Approach with Feature Selection.
    Wang S; Zhang YH; Zhang N; Chen L; Huang T; Cai YD
    Comb Chem High Throughput Screen; 2017; 20(7):582-593. PubMed ID: 28294058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodologies and strategies for the bioengineering of lantibiotics.
    Nagao J; Nishie M; Sonomot K
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1221-30. PubMed ID: 21470152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Gut-Derived Nisin-like Lantibiotics against Human Gut Pathogens and Commensals.
    Zhang ZJ; Wu C; Moreira R; Dorantes D; Pappas T; Sundararajan A; Lin H; Pamer EG; van der Donk WA
    ACS Chem Biol; 2024 Feb; 19(2):357-369. PubMed ID: 38293740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multipronged approach for engineering novel peptide analogues of existing lantibiotics.
    Escano J; Smith L
    Expert Opin Drug Discov; 2015; 10(8):857-70. PubMed ID: 26004576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lantibiotics: diverse activities and unique modes of action.
    Asaduzzaman SM; Sonomoto K
    J Biosci Bioeng; 2009 May; 107(5):475-87. PubMed ID: 19393544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein engineering of lantibiotics.
    Kuipers OP; Bierbaum G; Ottenwälder B; Dodd HM; Horn N; Metzger J; Kupke T; Gnau V; Bongers R; van den Bogaard P; Kosters H; Rollema HS; de Vos WM; Siezen RJ; Jung G; Götz F; Sahl HG; Gasson MJ
    Antonie Van Leeuwenhoek; 1996 Feb; 69(2):161-69. PubMed ID: 8775976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the attrition rate of Lanthipeptide discovery for commercial applications.
    Geng M; Smith L
    Expert Opin Drug Discov; 2018 Feb; 13(2):155-167. PubMed ID: 29195488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type AII lantibiotic bovicin HJ50 with a rare disulfide bond: structure, structure-activity relationships and mode of action.
    Zhang J; Feng Y; Teng K; Lin Y; Gao Y; Wang J; Zhong J
    Biochem J; 2014 Aug; 461(3):497-508. PubMed ID: 24814218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lantibiotics: insight and foresight for new paradigm.
    Nagao J; Asaduzzaman SM; Aso Y; Okuda K; Nakayama J; Sonomoto K
    J Biosci Bioeng; 2006 Sep; 102(3):139-49. PubMed ID: 17046525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.
    Escano J; Stauffer B; Brennan J; Bullock M; Smith L
    Microbiologyopen; 2014 Dec; 3(6):961-72. PubMed ID: 25400246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Employing the promiscuity of lantibiotic biosynthetic machineries to produce novel antimicrobials.
    Montalbán-López M; van Heel AJ; Kuipers OP
    FEMS Microbiol Rev; 2017 Jan; 41(1):5-18. PubMed ID: 27591436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class I and Class II Lanthipeptides Produced by Bacillus spp.
    Barbosa J; Caetano T; Mendo S
    J Nat Prod; 2015 Nov; 78(11):2850-66. PubMed ID: 26448102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome database mining for the discovery of novel lantibiotics.
    Sandiford SK
    Expert Opin Drug Discov; 2017 May; 12(5):489-495. PubMed ID: 28306363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-peptide lantibiotics: a medical perspective.
    Lawton EM; Ross RP; Hill C; Cotter PD
    Mini Rev Med Chem; 2007 Dec; 7(12):1236-47. PubMed ID: 18220976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.